{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:24:21Z","timestamp":1787293461843,"version":"build-2736575974"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lipoprotein(a) [Lp(a)] is synthesized mainly in the liver, whereas blood cell-derived inflammatory indices reflect systemic immune\u2013inflammatory status. We examined their associations with FibroTouch-assessed hepatic steatosis and liver stiffness in Chinese adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This hospital-based cross-sectional study included 1,345 Chinese adults. Nonalcoholic fatty liver disease (NAFLD) was defined as controlled attenuation parameter (CAP) \u2265248 dB\/m, and elevated liver stiffness as liver stiffness measurement (LSM) \u22658 kPa. Multivariable logistic and linear regression, restricted cubic spline (RCS), receiver operating characteristic (ROC), joint-exposure, subgroup, and sensitivity analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Higher Lp(a) quartiles were associated with lower prevalences of NAFLD and elevated liver stiffness and with lower CAP and LSM values. After full adjustment, the highest versus lowest quartile was associated with lower odds of NAFLD (odds ratio [OR], 0.28; 95% confidence interval [CI], 0.20\u20130.41) and elevated liver stiffness (OR, 0.31; 95% CI, 0.21\u20130.45). RCS analyses showed significant inverse associations without evidence of nonlinearity. Higher Lp(a) was also associated with lower CAP (\u03b2, \u221214.40; 95% CI, \u221217.79 to \u221211.01) and LSM (\u03b2, \u22120.58; 95% CI, \u22120.83 to \u22120.33). The Lp(a)\u2013systemic immune-inflammation index (SII) combination showed the highest discrimination for NAFLD, whereas Lp(a)\u2013systemic inflammation response index (SIRI) performed best for elevated liver stiffness. When added to the fully adjusted model, the corresponding areas under the ROC curve (AUCs) were 0.762 and 0.811, respectively, and exceeded those of established noninvasive fibrosis scores. Low Lp(a) combined with high inflammatory burden was associated with the highest odds of both outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among Chinese adults, higher circulating Lp(a) was inversely associated with FibroTouch-derived hepatic steatosis and liver stiffness. Combining Lp(a) with systemic inflammatory indices may provide complementary information for noninvasive cross-sectional assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1926199","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:37:28Z","timestamp":1787290648000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Joint associations of lipoprotein(a) and systemic inflammatory indices with FibroTouch-derived hepatic steatosis and liver stiffness in Chinese adults"],"prefix":"10.3389","volume":"17","author":[{"given":"Dejin","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Traditional and Western Medical Hepatology, Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, The Third Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Sun","sequence":"additional","affiliation":[{"name":"Medical School, Nanjing University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Traditional and Western Medical Hepatology, Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, The Third Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Traditional and Western Medical Hepatology, Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, The Third Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Traditional and Western Medical Hepatology, Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, The Third Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Traditional and Western Medical Hepatology, Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, The Third Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Traditional and Western Medical Hepatology, Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, The Third Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Health Management Center, Baoding People\u2019s Hospital","place":["Baoding, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Traditional and Western Medical Hepatology, Hebei Provincial Key Laboratory of Liver Fibrosis in Chronic Liver Diseases, The Third Hospital of Hebei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/ijms232415489","article-title":"Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment","volume":"23","author":"Guo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2851","article-title":"Role of lipoprotein(a) in atherosclerotic cardiovascular disease: a review of current and emerging therapies","volume":"43","author":"Alhomoud","year":"2023","journal-title":"Pharmacotherapy"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000504","article-title":"The ability of lipoprotein (a) level to predict early carotid atherosclerosis is impaired in patients with advanced liver fibrosis related to metabolic-associated fatty liver disease","volume":"13","author":"Wu","year":"2022","journal-title":"Clin Transl Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-023-01457-2","article-title":"Association between hepatic steatosis and lipoprotein(a) levels in non-alcoholic patients: a systematic review","volume":"43","author":"Masson","year":"2024","journal-title":"Indian J Gastroenterol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12944-020-01310-x","article-title":"Lipoprotein a, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study","volume":"19","author":"Zhang","year":"2020","journal-title":"Lipids Health Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"8538","DOI":"10.1038\/s41598-025-93518-z","article-title":"There is a linear negative correlation between lipoprotein(a) and non-alcoholic fatty liver disease","volume":"15","author":"Li","year":"2025","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines14030539","article-title":"The effectiveness of current inflammatory indices and clinical scores in early diagnosis and predicting long-term mortality in patients with chronic heart failure","volume":"14","author":"Cakmak","year":"2026","journal-title":"Biomedicines"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"Hammerich","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/jci88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132755","article-title":"The relationship between composite inflammatory indicators and short-term outcomes in patients with heart failure","volume":"420","author":"Yang","year":"2025","journal-title":"Int J Cardiol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fimmu.2025.1702567","article-title":"Associations between composite systemic inflammation indicators(CAR, CLR, SII, AISI, SIRI, and CALLY) and metabolic dysfunction-associated fatty liver disease (MAFLD): evidence from a two-stage study in China","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1371\/journal.pone.0312877","article-title":"Chronic systemic inflammation predicts long-term mortality among patients with fatty liver disease: data from the National Health and Nutrition Examination Survey 2007-2018","volume":"19","author":"Pan","year":"2024","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1186\/s12876-025-04210-5","article-title":"AISI and MASLD: a nonlinear association in U.S. adults (NHANES 2017-2020)","volume":"25","author":"Xiao","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.14218\/jcth.2024.00311","article-title":"Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)","volume":"32","year":"2024","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.14218\/jcth.2024.00311","article-title":"Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (Version 2024)","volume":"12","author":"Fan","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/NT.0000000000000092","article-title":"Body mass index: obesity, BMI, and health: a critical review","volume":"50","author":"Nuttall","year":"2015","journal-title":"Nutr Today"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112148-20240102-00002","article-title":"Chinese guideline for lipid management (primary care version 2024)","volume":"52","year":"2024","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26599\/1671-5411.2025.01.008","article-title":"Chinese guidelines for the prevention and treatment of hypertension (2024 revision)","volume":"22","author":"Wang","year":"2025","journal-title":"J Geriatr Cardiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-0442","article-title":"Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma","volume":"20","author":"Hu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30057","article-title":"A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy","volume":"122","author":"Qi","year":"2016","journal-title":"Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184134","article-title":"The aggregate index of systemic inflammation (AISI): a novel prognostic biomarker in idiopathic pulmonary fibrosis","volume":"10","author":"Zinellu","year":"2021","journal-title":"J Clin Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/sim.9259","article-title":"Using fractional polynomials and restricted cubic splines to model non-proportional hazards or time-varying covariate effects in the Cox regression model","volume":"41","author":"Austin","year":"2022","journal-title":"Stat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0331756","article-title":"Can lipid indices aid in predicting diabetic kidney disease? Findings from a cross-sectional, matched case-control study","volume":"20","author":"Yadegar","year":"2025","journal-title":"PloS One"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29639","article-title":"Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis","volume":"67","author":"Caussy","year":"2018","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.06.004","article-title":"Establishing age and sex dependent upper reference limits for the plasma lipoprotein (a) in a Chinese health check-up population and according to its relative risk of primary myocardial infarction","volume":"484","author":"Cui","year":"2018","journal-title":"Clin Chim Acta"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1190934","article-title":"2023 Chinese guideline for lipid management","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent insights into the pathogenesis of nonalcoholic fatty liver disease","volume":"13","author":"Arab","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2020.02.026","article-title":"Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor","volume":"299","author":"Konishi","year":"2020","journal-title":"Atherosclerosis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1830","article-title":"Low lipoprotein(a) levels predict hepatic fibrosis in patients with nonalcoholic fatty liver disease","volume":"6","author":"Meroni","year":"2022","journal-title":"Hepatol Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2016.07.003","article-title":"Association between lipoprotein(a) and nonalcoholic fatty liver disease among Korean adults","volume":"461","author":"Nam","year":"2016","journal-title":"Clin Chim Acta"},{"key":"B39","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-026-03289-8","article-title":"Sex- and menopause-specific inverse associations between metabolic dysfunction-associated steatotic liver disease and serum lipoprotein(a) concentrations: evidence from SHIP and UK Biobank","volume":"25","author":"de Souza","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.10.018","article-title":"Lipoprotein (a) in the full spectrum of metabolic dysfunction-associated steatotic liver disease: evidence from histologically and genetically characterized cohorts","volume":"23","author":"Fan","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16768","article-title":"Circulating lipoprotein(a) in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"39","author":"Nikoli","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"101309","DOI":"10.1016\/j.jacbts.2025.05.004","article-title":"The cardiohepatic axis in metabolic disease: liver to heart","volume":"10","author":"Hakeem","year":"2025","journal-title":"JACC Basic Transl Sci"},{"key":"B44","doi-asserted-by":"publisher","first-page":"12829","DOI":"10.1038\/s41598-024-63381-5","article-title":"Association of systemic inflammatory indices with anthropometric measures, metabolic factors, and liver function in non-alcoholic fatty liver disease","volume":"14","author":"Arefhosseini","year":"2024","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1702567","article-title":"Associations between composite systemic inflammation indicators(CAR, CLR, SII, AISI, SIRI, and CALLY) and metabolic dysfunction-associated fatty liver disease (MAFLD): evidence from a two-stage study in China","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2023.102536","article-title":"The association of systemic inflammatory biomarkers with non-alcoholic fatty liver disease: a large population-based cross-sectional study","volume":"37","author":"Sun","year":"2024","journal-title":"Prev Med Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.925690","article-title":"Association between SII and hepatic steatosis and liver fibrosis: a population-based study","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.04.018","article-title":"The systemic inflammation response index as a risk factor for hepatic fibrosis and long-term mortality among individuals with metabolic dysfunction-associated steatotic liver disease","volume":"34","author":"Yin","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1926199\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:37:30Z","timestamp":1787290650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1926199\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2026.1926199"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1926199","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1926199"}}